ArticleProceedings of the National Academy of Sciences of the United States of America2025
Distinct and convergent effects of
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Distinct and convergent effects ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Riley E BergmanMedical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, TN 37240.ORCID 0000-0003-0946-8913
Christin I KeetonDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.
Irika R SinhaDepartment of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205.ORCID 0000-0001-6440-7019
Jonathan P LingDepartment of Pathology, Division of Neuropathology, Johns Hopkins University, Baltimore, MD 21287.ORCID 0000-0003-1927-9729
Yu WangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37203.ORCID 0000-0002-2819-4551
Lauren HaDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0009-0005-9441-2659
Eshani P MehtaDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.
Sarah C ReedMedical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, TN 37240.ORCID 0000-0003-2191-6643
Ethan K FoxDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.
Tina M O'GradyTempus AI, Inc., Chicago, IL 60654.
Yingying YuTempus AI, Inc., Chicago, IL 60654.ORCID 0009-0004-7828-8646
Stamatina FragkogianniTempus AI, Inc., Chicago, IL 60654.
Calvin ChaoTempus AI, Inc., Chicago, IL 60654.
Brad A DavidsonDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.
Adam X MirandaDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0000-0002-3140-1953
Sarah CroessmannDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0000-0002-7366-0400
Shilin ZhaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37203.
Qi LiuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37203.ORCID 0000-0001-8892-7078
Yu ShyrDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37203.
W Brian DaltonThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 19107.ORCID 0000-0002-1314-0534
Paula J HurleyDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.
Ben H ParkDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232.ORCID 0000-0001-8119-2291
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MTranslational Pathology CoreU54CA163069 · NCI · MEHARRY MEDICAL COLLEGE · PI BALLARD, BILLY RAY · 2011 to 2025
$18.8MMedical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8MCirculating plasma tumor DNA as a biomarker for early stage breast cancerR01CA194024 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO · 2016 to 2020
$1.9MRegulation of Metastatic Development by Heritable Variants in the Tumor MicroenvironmentR01CA211695 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HURLEY, PAULA JILL · 2018 to 2023
$1.9MEnabling Technology to Study Mechanosensitive and Mechanoresistant Cancer Cells in FlowR01CA256054 · NCI · VANDERBILT UNIVERSITY · PI KING, MICHAEL R. · 2021 to 2025
$1.8MDefining Tumor Microenvironmental Mediators of Prostate Cancer Metastasis and Therapy ResistanceR01CA285780 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paula Jill Hurley · 2024 to 2026
$1.7MMolecular Mediators of Cell-free DNA biogenesisR01CA289528 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 2025 to 2026
$1.3MMolecular complete response in blood as a predictor for pathologic complete response after neoadjuvant therapy for breast cancerR01CA214494 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO · 2018 to 2023
$1.1MEnhanced Genetic Targeting of Specific Neuronal Populations Using a Minipromoter and Splicing Hybrid ApproachR21NS135454 · NINDS · TUFTS UNIVERSITY BOSTON · PI BYGRAVE, ALEXEI MANSFIELD, LING, JONATHAN · 2024 to 2024
$468kAmerican Cancer Society (ACS) 131356-RSG-17-160-01-CSMHHS | NIH | National Cancer Institute (NCI) 1R01CA285780-01A1HHS | NIH | National Cancer Institute (NCI) CA194024HHS | NIH | National Cancer Institute (NCI) CA214494HHS | NIH | National Cancer Institute (NCI) CA289528HHS | NIH | National Cancer Institute (NCI) F30CA268325HHS | NIH | National Cancer Institute (NCI) F30CA284523HHS | NIH | National Cancer Institute (NCI) R01CA211695-01A1HHS | NIH | National Cancer Institute (NCI) R01CA256054-01A1HHS | NIH | National Cancer Institute (NCI) U54CA163069-11HHS | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007347HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R21NS135454NCI NIH HHS F30 CA268325NCI NIH HHS F30 CA284523NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA194024NCI NIH HHS R01 CA211695NCI NIH HHS R01 CA214494NCI NIH HHS R01 CA256054NCI NIH HHS R01 CA285780NCI NIH HHS R01 CA289528NCI NIH HHS U54 CA163069NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM152284NINDS NIH HHS R21 NS135454NSF | NSF Graduate Research Fellowship Program (GRFP) DGE2139757Susan G. Komen (SGK) SAC170079
Abstract
Tumor genomic profiling has uncovered many cancer drivers whose implications in terms of tumor biology and therapeutic actionability remain understudied. Hotspot mutations in
Indexed as
Breast NeoplasmsMutationPhosphoproteinsRNA Splicing FactorsAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMicePhosphoproteinsRNA Splicing FactorsSF3B1 protein, humanbreast canceroncogeneselectionSF3B1splicing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.